Bristol-Myers Subpoenaed Over Plavix Deal
The request for information from the U.S. Federal Trade Commission was revealed on March 21 in Bristol-Myers Squibb’s annual regulatory filing with the U.S. Securities and Exchange Commission.
The New York-based company said in a statement that it plans to cooperate fully with the investigation. The deal at the center of the probe...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login